[go: up one dir, main page]

NO963568D0 - Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse - Google Patents

Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse

Info

Publication number
NO963568D0
NO963568D0 NO963568A NO963568A NO963568D0 NO 963568 D0 NO963568 D0 NO 963568D0 NO 963568 A NO963568 A NO 963568A NO 963568 A NO963568 A NO 963568A NO 963568 D0 NO963568 D0 NO 963568D0
Authority
NO
Norway
Prior art keywords
preparation
treatment
methods
pharmaceutical composition
blood coagulation
Prior art date
Application number
NO963568A
Other languages
English (en)
Other versions
NO963568L (no
Inventor
Peter Turecek
Hans-Peter Schwarz
Gerda Redt
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO963568D0 publication Critical patent/NO963568D0/no
Publication of NO963568L publication Critical patent/NO963568L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO963568A 1995-08-28 1996-08-27 Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse NO963568L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19531637A DE19531637A1 (de) 1995-08-28 1995-08-28 Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung

Publications (2)

Publication Number Publication Date
NO963568D0 true NO963568D0 (no) 1996-08-27
NO963568L NO963568L (no) 1997-03-03

Family

ID=7770599

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963568A NO963568L (no) 1995-08-28 1996-08-27 Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse

Country Status (6)

Country Link
US (2) US5891843A (no)
EP (1) EP0765669A1 (no)
JP (1) JPH09110715A (no)
CA (1) CA2184226A1 (no)
DE (1) DE19531637A1 (no)
NO (1) NO963568L (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ81997A3 (en) * 1996-03-20 1997-10-15 Immuno Ag Pharmaceutical preparation for treating disorders connected with blood clotting, process of its preparation and use
WO1998044942A1 (de) 1997-04-08 1998-10-15 Baxter Aktiengesellschaft Immuntolerante prothrombinkomplex-präparation
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
JP4676585B2 (ja) 1999-12-24 2011-04-27 一般財団法人化学及血清療法研究所 血液凝固異常に基づく疾患の治療・予防用医薬組成物
EP1982732A3 (en) * 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
HUP0303130A2 (hu) * 2001-02-05 2004-01-28 Novo Nordisk Health Care Ag A VII-es faktor és a VIII-as faktor polipeptidek kombinált alkalmazása és ezeket tartalmazó gyógyszerkészítmények
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7329724B2 (en) 2001-07-10 2008-02-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
PL370652A1 (en) 2001-12-21 2005-05-30 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
NZ536340A (en) * 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
DK2283856T3 (da) 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
US7968515B2 (en) * 2002-09-30 2011-06-28 Socratech L.L.C. Protein S protects the nervous system from injury
US20040198660A1 (en) * 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1611236A1 (en) * 2003-03-18 2006-01-04 Novo Nordisk Health Care AG Method for the production of gla-residue containing serine proteases
ES2327044T3 (es) * 2003-03-20 2009-10-23 Bayer Healthcare Llc Variantes de fvii o fviia.
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2465004A1 (en) * 2003-05-19 2004-11-19 National Institute For Biological Standards And Control Composition
JP5627832B2 (ja) 2003-05-23 2014-11-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 溶液中におけるタンパク質の安定化
WO2004111242A1 (en) 2003-06-19 2004-12-23 Maxygen Holdings Ltd. FACTOR VII OR VIIa GLA DOMAIN VARIANTS
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
AU2004298789A1 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
ES2339953T5 (es) 2004-05-04 2020-05-06 Novo Nordisk Healthcare Ag Glicoformas de factor VII ligadas a O y método de fabricación
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
EP1797180A2 (en) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
US20070129298A1 (en) * 2005-07-22 2007-06-07 Maxygen Holdings, Ltd. In-solution activation of factor vii
US7807435B2 (en) * 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
ES2257225B1 (es) * 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
TWI684599B (zh) * 2014-08-12 2020-02-11 美商巴克斯歐塔公司 因子ｘ活化

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT154793B (de) 1936-09-03 1938-10-25 Telefunken Gmbh Mehrgitterröhre.
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
DE3165600D1 (en) * 1980-01-28 1984-09-27 Baxter Travenol Lab Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4287180A (en) * 1980-01-28 1981-09-01 Baxter Travenol Laboratories, Inc. Method for treating blood clotting factor inhibitors
US4364861A (en) * 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
EP0124506B1 (de) * 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
DE3740520A1 (de) * 1987-11-30 1989-06-08 Hans Dr Rer Nat Scheefers Schnelles verfahren zur gewinnung einer faktor vii - praeparation sowie ihre verwendung
FR2632524B1 (fr) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5094165A (en) * 1989-08-04 1992-03-10 Komori Corporation Plate lockup apparatus for sheet-fed press
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
FR2684999A1 (fr) * 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
AT402151B (de) * 1993-08-03 1997-02-25 Immuno Ag Verfahren zur herstellung eines virussicheren biologischen präparates

Also Published As

Publication number Publication date
US6013620A (en) 2000-01-11
EP0765669A1 (de) 1997-04-02
JPH09110715A (ja) 1997-04-28
CA2184226A1 (en) 1997-03-01
US5891843A (en) 1999-04-06
NO963568L (no) 1997-03-03
DE19531637A1 (de) 1997-03-06

Similar Documents

Publication Publication Date Title
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
NO951761D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
HUP9700603A3 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
NO911952D0 (no) Behandling av sykdomstilstander, middel derfor og dets fremstilling.
NO972972D0 (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
NO20001754D0 (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
NO20001001D0 (no) Poly (ADP-ribose) polymerase ("PARP") inhibitorer, fremgangsmõte og farmasøytiske sammensetninger for behandling av neurale og kardiovaskulære vevskader
NO20010593L (no) Preparat og fremgangsmÕte for behandling av Peyronies sykdom og andre subdermale plakkmanifestasjonsforstyrrelser
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
FI963696L (fi) Geeli ihosairauksien hoitoon ja ihon desinfiointiin
IT9048260A0 (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
NO20005387D0 (no) 3-(amino- eller aminoalkyl-)pyridinonderivater og deres anvendelse for behandling av HIV-relaterte sykdommer
FI971951L (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
NO20011409L (no) Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
IT9048261A0 (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
NO307930B1 (no) Benzo[f]kinolinoner, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av formulering for behandling
NO973342D0 (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
NO991164D0 (no) Farmas°ytisk preparat for behandling av virussykdommer
NO951762D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff
MA26648A1 (fr) Associations thérapeutiques pour le traitement de maladies osseuses, et procédé pour leur préparation.
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application